A phase 2 multiple ascending dose study of the inhaled pan-JAK inhibitor nezulcitinib (TD-0903) in severe COVID-19.
Singh D, Bogus M, Moskalenko V, Lord R, Moran EJ, Crater GD, Bourdet DL, Pfeifer ND, Woo J, Kaufman E, Lombardi DA, Weng EY, Nguyen T, Woodcock A, Haumann B, Saggar R.
Singh D, et al. Among authors: bourdet dl.
Eur Respir J. 2021 Oct 14;58(4):2100673. doi: 10.1183/13993003.00673-2021. Print 2021 Oct.
Eur Respir J. 2021.
PMID: 34210790
Free PMC article.
Clinical Trial.